Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TKTX is a brand of topical anesthetic products formulated primarily for temporary pain relief during cosmetic and dermatological procedures such as tattooing, laser treatments, waxing, microneedling, and minor surgical interventions. The formulations vary but commonly include local anesthetics such as lidocaine (in concentrations ranging from 7% to 22%), prilocaine (up to 7%), tetracaine (up to 3%), procaine (5%), and sometimes epinephrine/adrenaline (up to 2%). These agents act by blocking sodium channels in neuronal membranes at the site of application, thereby inhibiting nerve signal transmission and producing localized numbness. Some versions are marketed with claims of rapid onset and prolonged duration of action—numbing effects can last from three up to eight hours depending on the formulation and skin type. The products are available over-the-counter in some regions but are not approved or regulated by major health authorities like the FDA or EMA; several regulatory agencies have issued warnings regarding their unauthorized status and potential safety risks due to unverified composition[1][3][4][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TKTX.